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1. Introduction
Tamoxifen is still the treatment of choice in the ad-
juvant setting in pre- and post-menopausal women with
breast cancer and also the ﬁrst choice in the palliative
treatment of women with metastatic breast cancer [1].
This update considers the side-eﬀects of tamoxifen on
the female genital tract in pre- and post-menopausal
women.
2. Results
Tamoxifen has oestrogen agonistic and antagonistic
eﬀects on gynaecological tissues and organs, depending
on the ambient oestradiol concentration [2].
In pre-menopausal tamoxifen users, ovarian cysts
occur in over 80%, resulting in high serum levels of
oestradiol, while serum levels of FSH and LH are only
minimally inﬂuenced [3]. Oligo- and amenorrhoea occur
in half of the patients. Tamoxifen has an antagonistic
eﬀect on the endometrium in pre-menopausal women
[4]. Even in women with supraphysiological serum levels
of oestradiol, the endometrial lining stays thin. Ta-
moxifen is associated with impaired sexual functioning
and hot ﬂushes. Tamoxifen might be teratogenic.
In post-menopausal women, tamoxifen has an oestro-
gen agonistic eﬀect on the uterus. Tamoxifen can induce
benign endometrial stromal hyperplasia and endometrial
polyps. Tamoxifen-exposure up to ﬁve years increases the
endometrial cancer risk by two- to three-fold [5]. There is
no general consensus regarding endometrial surveillance
in post-menopausal tamoxifen users. In Europe, opinions
about endometrial surveillance vary from no screening to
pre-treatment ultrasound and subsequent annual
screening three years after the start of tamoxifen [6,7]. No
trials exist on the eﬃcacy of pre-symptomatic screening.
Women with tamoxifen-induced endometrial cancer
present with post-menopausal bleeding in the same way
as non-users. Endometrial surveillance by ultra-
sonography has a high false-positive rate due to tamox-
ifen-induced characteristic sonographic changes of the
post-menopausal endometrium, hampering its inter-
pretation [8]. Endometrial sonographic screening in
asymptomatic tamoxifen users is not likely to be eﬀective
in lowering morbidity or mortality from endometrial
cancer. Instead, patients need to be educated to report
vaginal bleeding immediately. In all cases of post-me-
nopausal bleeding, histology of the endometrium is in-
dicated. Tamoxifen can aggravate symptoms of hot
ﬂashes and sexual dysfunction [9]. No recommendations
exist about irregular vaginal bleeding in perimenopausal
women. The irregular cycles in these women hamper the
signal function of vaginal bleeding and they should be
advised to be seen by a gynaecologist to exclude en-
dometrial cancer.
3. Conclusions
Despite its side-eﬀects on the female genital tract and
psychosexual functioning, of which patients need to be
informed, the beneﬁts of tamoxifen outweigh the risks.
Patients need to be educated to report abnormal
bleeding or discharge without delay.
References
1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical
Oncology Technology Assessement on the aromatase inhibitors as
*Corresponding author. Tel.: +31 503611806; fax: +31 503613152.
E-mail address: m.j.e.mourits@og.azg.nl. (M.J. Mourits).
1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejcsup.2004.08.004
EJC Supplements Vol 2 No. 9 (2004) 22–23
www.ejconline.com
EJC
Supplements
adjuvant therapy for women with hormone receptor positive breast
cancer status report 2002. J Clin Oncol 2002, 20, 3317–3327.
2. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema
H, Van der Zee AG. Tamoxifen treatment and gynaecologic side
eﬀects: a review. Obstet Gynecol 2001, 97, 855–858.
3. Mourits MJE, De Vries EGE, Willemse PHB, et al. Ovarian cysts in
women receiving tamoxifen for breast cancer. Br J Cancer 1999, 79,
1761–1764.
4. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M.
Variation in endometrial thickening in women with amenorrhea on
tamoxifen. Breast Cancer Res Treat 1998, 48, 81–85.
5. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van
Leeuwen FE. Risk and prognosis of endometrial cancer after
tamoxifen for breast cancer. Comprehensive Cancer Centres
ALERT Group. Assessment of Liver and Endometrial Cancer Risk
following Tamoxifen. Lancet 2000, 356, 881–887.
6. Mourits MJ, Willemse PH, de Vries EG, van der Zee AG.
Tamoxifen and endometrial screening. J Clin Oncol 2000, 18, 446–
468.
7. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D.
Endometrial disorders in 406 breast cancer patients on tamoxifen:
the case for less intensive screening. Eur J Obstet Gynecol Reprod
Biol 2002, 101, 58–63.
8. Mourits MJE, Van der Zee AGJ, Willemse PHB, Ten Hoor KA,
Hollema H, De Vries EGE. Discrepancy between ultrasonographic
and hysteroscopic and pathologic endometrial ﬁndings in post-
menopausal breast cancer patients using tamoxifen. Gynecol Oncol
1999, 73, 21–26.
9. Mourits MJ, Bockermann I, de Vries EG, et al. Tamoxifen eﬀects on
subjective and psychosexual well-being, in a randomised breast
cancer study comparing high-dose and standard-dose chemother-
apy. Br J Cancer 2002, 86, 1546–1550.
M.J. Mourits et al. / EJC Supplements Vol 2 No. 9 (2004) 22–23 23
